MARA Ratings Catalogue

Standardized Reimbursement Risk Assessments Across Therapeutic Areas

This page provides access to the complete catalogue of MARA Ratings® — independent, committee-determined reimbursement risk ratings, built for high-stakes market access and due diligence decisions across therapeutic areas, indications, and launch stages.

Each listing is a standardized reimbursement risk rating: the same ten-domain method for every asset, assessed in the payer context of the US, EU4, UK, and Japan, and calibrated against historical Health Technology Assessment (HTA) decisions.

A MARA Rating is a standardized risk signal, not an advisory opinion. It is structured, evidence-linked, and comparable across assets — an independent benchmark for pricing, reimbursement, and market-access assumptions before major capital allocation, licensing, M&A, or launch commitments are made. Once published, a rating stays on the record.